Compare PM & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PM | AZN |
|---|---|---|
| Founded | 1987 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.8B | 276.3B |
| IPO Year | N/A | 1993 |
| Metric | PM | AZN |
|---|---|---|
| Price | $149.44 | $91.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $190.44 | N/A |
| AVG Volume (30 Days) | 5.3M | ★ 5.5M |
| Earning Date | 10-21-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.93% | 1.68% |
| EPS Growth | N/A | ★ 45.02 |
| EPS | 5.52 | ★ 6.02 |
| Revenue | $39,992,000,000.00 | ★ $58,127,000,000.00 |
| Revenue This Year | $10.82 | $11.33 |
| Revenue Next Year | $7.66 | $6.08 |
| P/E Ratio | $27.12 | ★ $15.20 |
| Revenue Growth | 7.45 | ★ 13.52 |
| 52 Week Low | $116.12 | $61.24 |
| 52 Week High | $186.69 | $94.02 |
| Indicator | PM | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 60.08 |
| Support Level | $146.65 | $89.67 |
| Resistance Level | $150.89 | $91.28 |
| Average True Range (ATR) | 3.22 | 1.45 |
| MACD | -0.60 | -0.30 |
| Stochastic Oscillator | 25.97 | 55.58 |
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heat sticks, vapes, and oral nicotine offerings, primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI is not only dominant in smokable products but also has the Iqos and Zyn brands, which respectively dominate heated tobacco and nicotine pouches in most markets.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.